News

Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025

Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes…

9 months ago

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with…

9 months ago

Save the Date: Profound Medical to Host Investor Event at AUA 2025

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device…

9 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

9 months ago

MUHC Foundation Receives $2 million Donation to establish the MUHC’s Metabolic Centre of Excellence

MUHC Foundation Receives $2 million Donation to establish the MUHC’s Metabolic Centre of Excellence Marie-Hélène Laramée, Dr. Michael Tsoukas, Vince…

9 months ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene…

9 months ago

Prime Biome Reviews (Is It Legit And Safe Ingredients?) Can This Probiotic Really Transform Your Skin And Gut?

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- The Prime Biome probiotic supplement that has been garnering attention in the health…

9 months ago

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a…

9 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target…

9 months ago

Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology

CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug…

9 months ago